ITEM VIEW

Xpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposure

dc.contributor.authorJayakumar, A.en_ZA
dc.contributor.authorSavic, R. M.en_ZA
dc.contributor.authorEverett, C. K.en_ZA
dc.contributor.authorBenator, D.en_ZA
dc.contributor.authorAlland, D.en_ZA
dc.contributor.authorHeilig, C. M.en_ZA
dc.contributor.authorWeiner, M.en_ZA
dc.contributor.authorFriedrich, S. O.en_ZA
dc.contributor.authorMartinson, N. A.en_ZA
dc.contributor.authorKerrigan, A.en_ZA
dc.contributor.authorZamudio, C.en_ZA
dc.contributor.authorGoldberg, S. V.en_ZA
dc.contributor.authorWhitworth, W. C.en_ZA
dc.contributor.authorDavis, J. L.en_ZA
dc.contributor.authorNahid, P.en_ZA
dc.date.accessioned2018-09-13T07:44:11Z
dc.date.available2018-09-13T07:44:11Z
dc.date.issued2016-12
dc.identifier.citationJayakumar, A. et al. 2016. Xpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposure. Journal of Clinical Microbiology, 54(12):3028 –3033, doi:10.1128/JCM.01313-16.
dc.identifier.issn1098-660X (online)
dc.identifier.issn0095-1137 (print)
dc.identifier.otherdoi:10.1128/JCM.01313-16
dc.identifier.urihttp://hdl.handle.net/10019.1/104421
dc.descriptionCITATION: Jayakumar, A. et al. 2016. Xpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposure. Journal of Clinical Microbiology, 54(12):3028 –3033, doi:10.1128/JCM.01313-16.
dc.descriptionThe original publication is available at https://jcm.asm.org
dc.description.abstractThe Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (CT ) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in CT (P = 0.02). The estimated increase in CT slope for every additional 100 μg · h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT /week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT , indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.en_ZA
dc.description.urihttps://jcm.asm.org/content/54/12/3028
dc.format.extent6 pages
dc.language.isoen_ZAen_ZA
dc.publisherAmerican Society for Microbiology
dc.subjectTuberculosisen_ZA
dc.subjectRifapentineen_ZA
dc.titleXpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposureen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyright


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW